Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by FARR, M.
Right arrow Articles by BACON, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FARR, M.
Right arrow Articles by BACON, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

other

SULPHASALAZINE IN PSORIATIC ARTHRITIS: A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

MARGARET FARR*,, G. D. KITAS*, L. WATERHOUSE*, R. JUBB*, D. FELIXDAVIES{dagger} and P. A. BACON*

*Department of Rheumatology, University of Birmingham, The Medical School Birmingham B15 2TJ;
{dagger}Rheumatology Department, East Birmingham Hospital Birmingham 29

Correspondence to: Correspondence to Dr M. Farr.

Sulphasalazine (SASP) is now accepted as an effective slow-acting antirheumatic drug for treating active rheumatoid arthritis (RA), but has not been previously evaluated in psoriatic arthritis. An earlier open study suggested that it was well tolerated and potentially beneficial. The present double-blind placebo-controlled trial of 30 patients has now confirmed its efficacy. Greater improvement occurred in those patients on active treatment than on placebo, with more benefit being detected in those patients with the symmetrical polyarticular but seronegative pattern of arthritis associated with a high acute-phase response. SASP was stopped in 26% because of side-effects but these were mild. No exacerbation or remission of psoriasis was observed. Further studies are in progress to determine the degree of efficacy of SASP in different clinical subgroups of psoriatic arthritis.

KEY WORDS: Salazopyrin, Therapeutic response, Polyarthritis, Immunoglobulins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
V Ravindran, D L Scott, and E H Choy
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
Ann Rheum Dis, June 1, 2008; 67(6): 855 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Nash and D O Clegg
Psoriatic arthritis therapy: NSAIDs and traditional DMARDs
Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii74 - ii77.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
N Dalbeth, S Yeoman, J L Dockerty, J Highton, E Robinson, P L Tan, D Herman, and F M McQueen
A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis
Ann Rheum Dis, June 1, 2004; 63(6): 718 - 722.
[Abstract] [Full Text]

Home page
 Rheumatology (Oxford)Home page
N. Pipitone, G. H. Kingsley, A. Manzo, D. L. Scott, and C. Pitzalis
Current concepts and new developments in the treatment of psoriatic arthritis
Rheumatology, October 1, 2003; 42(10): 1138 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P J Mease
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors
Ann Rheum Dis, April 1, 2002; 61(4): 298 - 304.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J C Gerster and D Hohl
Nail lesions in psoriatic arthritis: recovery with sulfasalazine treatment
Ann Rheum Dis, March 1, 2002; 61(3): 277 - 277.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P J Mease
Cytokine blockers in psoriatic arthritis
Ann Rheum Dis, November 1, 2001; 60(90003): iii37 - 40.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.